219 related articles for article (PubMed ID: 10755723)
1. Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy.
Delcambre C; Reman O; Henry-Amar M; Peny AM; Macro M; Cheze S; Génot JY; Tanguy A; Switsers O; Van HL; Couëtte JE; Leporrier M; Bardet S
Eur J Nucl Med; 2000 Feb; 27(2):176-84. PubMed ID: 10755723
[TBL] [Abstract][Full Text] [Related]
2. Gallium-67 scintigraphy in lymphoma: is there a benefit of image fusion with computed tomography?
Chajari M; Lacroix J; Peny AM; Chesnay E; Batalla A; Henry-Amar M; Delcambre C; Génot JY; Fruchard C; Bardet S
Eur J Nucl Med Mol Imaging; 2002 Mar; 29(3):380-7. PubMed ID: 12002715
[TBL] [Abstract][Full Text] [Related]
3. Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma.
Zinzani PL; Zompatori M; Bendandi M; Battista G; Fanti S; Barbieri E; Gherlinzoni F; Rimondi MR; Frezza G; Pisi P; Merla E; Gozzetti A; Canini R; Monetti N; Babini L; Tura S
Leuk Lymphoma; 1996 Jun; 22(1-2):131-5. PubMed ID: 8724540
[TBL] [Abstract][Full Text] [Related]
4. 18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients.
Van Den Bossche B; Lambert B; De Winter F; Kolindou A; Dierckx RA; Noens L; Van De Wiele C
Nucl Med Commun; 2002 Nov; 23(11):1079-83. PubMed ID: 12411836
[TBL] [Abstract][Full Text] [Related]
5. Comparison of technetium-99m methoxyisobutylisonitrile and gallium-67 citrate scanning in the assessment of lymphomas.
Ziegels P; Nocaudie M; Huglo D; Deveaux M; Detourmignies L; Wattel E; Marchandise X
Eur J Nucl Med; 1995 Feb; 22(2):126-31. PubMed ID: 7758499
[TBL] [Abstract][Full Text] [Related]
6. Gallium scan in adolescents and children with Hodgkin's disease (HD). Treatment response assessment and prognostic value.
Castellani MR; Cefalo G; Terenziani M; Aliberti G; Maccauro M; Alessi A; Villano C; Bombardieri E
Q J Nucl Med; 2003 Mar; 47(1):22-30. PubMed ID: 12714951
[TBL] [Abstract][Full Text] [Related]
7. Comparison of gallium-67-citrate and thallium-201 scintigraphy in peripheral and intrathoracic lymphoma.
Waxman AD; Eller D; Ashook G; Ramanna L; Brachman M; Heifetz L; McAndrews P; Bierman H; Taub R; Avedo M; Wall F
J Nucl Med; 1996 Jan; 37(1):46-50. PubMed ID: 8544000
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma.
Sasaki M; Kuwabara Y; Koga H; Nakagawa M; Chen T; Kaneko K; Hayashi K; Nakamura K; Masuda K
Ann Nucl Med; 2002 Jul; 16(5):337-45. PubMed ID: 12230093
[TBL] [Abstract][Full Text] [Related]
9. The role of high dose 67-gallium scintigraphy in staging untreated patients with lymphoma.
Larcos G; Farlow DC; Antico VF; Gruenewald SM; Boyages J
Aust N Z J Med; 1994 Feb; 24(1):5-8. PubMed ID: 8002858
[TBL] [Abstract][Full Text] [Related]
10. Bone lymphoma: 67Ga scintigraphy and CT for prediction of outcome after treatment.
Israel O; Mekel M; Bar-Shalom R; Epelbaum R; Hermony N; Haim N; Dann EJ; Frenkel A; Ben-Arush M; Gaitini D
J Nucl Med; 2002 Oct; 43(10):1295-303. PubMed ID: 12368366
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
Shen YY; Kao A; Yen RF
Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
[TBL] [Abstract][Full Text] [Related]
12. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.
Wirth A; Seymour JF; Hicks RJ; Ware R; Fisher R; Prince M; MacManus MP; Ryan G; Januszewicz H; Wolf M
Am J Med; 2002 Mar; 112(4):262-8. PubMed ID: 11893364
[TBL] [Abstract][Full Text] [Related]
13. 67Ga scintigraphy for the evaluation of recurrences and residual masses in patients with lymphoma.
Setoain FJ; Pons F; Herranz R; Vidal-Sicart S; Lomeña F; Ayuso C; Montserrat E; Setoain J
Nucl Med Commun; 1997 May; 18(5):405-11. PubMed ID: 9194081
[TBL] [Abstract][Full Text] [Related]
14. [SPECT-CT 67Ga studies in lymphoma disease. Contribution to staging and follow-up].
Fuertes Manuel J; Estorch Cabrera M; Camacho Martí V; Flotats Giralt A; Rodríguez-Revuelto AA; Hernández Fructuoso MA; Carrió Gasset I
Rev Esp Med Nucl; 2006; 25(4):242-9. PubMed ID: 16827987
[TBL] [Abstract][Full Text] [Related]
15. Gallium-67 scintigraphy evaluation of therapy in non-Hodgkin's lymphoma.
Gasparini M; Bombardieri E; Castellani M; Tondini C; Maffioli L; Devizzi L; Gerundini P
J Nucl Med; 1998 Sep; 39(9):1586-90. PubMed ID: 9744348
[TBL] [Abstract][Full Text] [Related]
16. Comparison of bone and 67Ga scintigraphy in the initial diagnosis of bone involvement in children with malignant lymphoma.
Mouratidis B; Gilday DL; Ash JM
Nucl Med Commun; 1994 Mar; 15(3):144-7. PubMed ID: 8190402
[TBL] [Abstract][Full Text] [Related]
17. [Clinical usefulness of 67Ga-citrate scintigraphy combined early image in malignant lymphoma--detection of abdominal lesions].
Okazaki A; Katoh S; Noda M; Katsumata Y; Shirouzu I; Maehara T
Nihon Igaku Hoshasen Gakkai Zasshi; 1990 Aug; 50(8):1007-15. PubMed ID: 2235335
[TBL] [Abstract][Full Text] [Related]
18. The continuing clinical role of gallium 67 scintigraphy in the age of receptor imaging.
Front D; Bar-Shalom R; Israel O
Semin Nucl Med; 1997 Jan; 27(1):68-74. PubMed ID: 9122725
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study.
Bendini M; Zuiani C; Bazzocchi M; Dalpiaz G; Zaja F; Englaro E
MAGMA; 1996; 4(3-4):213-24. PubMed ID: 9220410
[TBL] [Abstract][Full Text] [Related]
20. Revisiting the prognostic role of gallium scintigraphy in low-grade non-Hodgkin's lymphoma.
Gallamini A; Biggi A; Fruttero A; Pugno F; Cavallero G; Pregno P; Grasso M; Farinelli C; Leone A; Gallo E
Eur J Nucl Med; 1997 Dec; 24(12):1499-506. PubMed ID: 9391185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
